Onkologie. 2011:5(2):96-98

Osteosarcoma: current options of diagnosis and treatment

Hubert Mottl1, Jarmila Kruseová1, Jiří Schovanec2
1 Klinika dětské hematologie a onkologie 2. LF UK a FNM, Praha
2 Ortopedická klinika 2. LF UK a FNM, Praha

Osteosarcoma (OS) is the most common malignant tumour of the skeleton accounting for approximately 35 % of primary bone tumours.

Successful treatment of osteosarcoma requires a close cooperation between the specialists of a multidisciplinary team consisting of an

oncologist, surgeon, pathologist and radiologist. The best care is provided by specialized centres with appropriate experience in which comprehensive

care is available. The therapeutic regimen must include radical removal of the primary tumour and/or metastases in combination

with systemic chemotherapy. The cytostatic drugs primarily used include doxorubicin, high-dose methotrexate, cisplatin and ifosfamide.

The goal of dividing chemotherapy into preoperative and postoperative parts is a reduction in the tumour mass and improved delineation

of the tumour from the surrounding structures. This improves the surgical radicality with the affected part of the skeleton being replaced

without the need for a mutilating procedure. Also of importance is the knowledge of the histopathological response to preoperative chemotherapy

which affects the intensity of postoperative treatment. The management of metastatic disease and possible recurrence has not

been addressed adequately as yet. Improved results can be expected with the introduction of novel therapeutic agents and modalities.

Keywords: osteosarcoma, children and adolescents

Published: April 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mottl H, Kruseová J, Schovanec J. Osteosarcoma: current options of diagnosis and treatment. Onkologie. 2011;5(2):96-98.
Download citation

References

  1. Arndt CA, Crist WM. Common muskuloskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352. Go to original source... Go to PubMed...
  2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1.702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790. Go to original source... Go to PubMed...
  3. Bielack SS, Jürgens H, Jundt G, et al. Osteosarcoma: the COSS experience. Cancer Treat Res 2009; 152: 289-308. Go to original source... Go to PubMed...
  4. Mottl H. Ewingův sarkom a osteosarkom. Sanquis 2007; 51: 18-20.
  5. Ozaki T, Flege S, Liljenquist U, et al. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer 2002; 94: 1069-1077. Go to original source... Go to PubMed...
  6. Fletcher CDM, Unni KK. Pathology and genetics of tumours of soft tissue and bone. In: Mertens F. editor. World Health Organization Classification f Tumours, Lyon, France: IARC Press; 2002-01-01.
  7. Stiller CA, Craft AW, Corazziari I. Survival of children with bone sarcoma in Europe since 1978: results form the EUROCARE study. Eur J Cancer 2001; 37: 760-766. Go to original source... Go to PubMed...
  8. Stiller CA, Bielack SS, Jundt G, et al. Bone tumours in European children and adolescents, 1978-1997. Report form the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42: 2124-2135.
  9. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 2010; 21: 320-325. Go to original source... Go to PubMed...
  10. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1.702 patients treated on neoadjuvant cooperative osteosarcoma study group protocol. J Clin Oncol 2002; 20: 776-790. Go to original source... Go to PubMed...
  11. Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children´s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51: 163-170. Go to original source... Go to PubMed...
  12. Wuisman P, Enneking WF. Prognosis of patients who have osteosarcoma with skip metastasis. J Bone Joint Surg 1990; 72A: 60-68. Go to original source...
  13. Kager L, Zoubek A, Kastner U, et al. Skip metastasis in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2006; 24: 1535-1541. Go to original source... Go to PubMed...
  14. Hawkins DS, Conrad EU 3rd, Butrynski JE, et al./F-18/fluorodeoxy-D-glucose-positron emission tomography response in association with outcome for extremity osteosarcoma in children and young adults. Cancer 2009; 115(15): 3519-3525. Go to original source... Go to PubMed...
  15. Costelloe CM, Macapinlac HA, Madewell JE, et al. 18-FDGPET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 2009; 50(3): 340-347. Go to original source... Go to PubMed...
  16. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-2177. Go to original source...
  17. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative Germ/ Austrian study. J Clin Oncol 1984; 2: 617-624. Go to original source... Go to PubMed...
  18. Link MO, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-1606. Go to original source... Go to PubMed...
  19. Eilber F, Giuliano A, Eckhardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5: 21-26. Go to original source... Go to PubMed...
  20. Kruseová J, Mottl H, Kodet R, et al. Radikální operační výkon a intenzivní chemoterapie jsou podmínkou úspěšné léčby osteosarkomu. Klin Onkol 2009; 22(4): 168-175. Go to PubMed...
  21. Mottl H, Mališ J, Starý J. Chemoterapie osteosarkomu a Ewingova sarkomu u dospívajících a mladých dospělých. XII. Annual National Congress of the Czech Society for Orthopaedics and Traumatology. 15.-17. 5. 2008, Prague, Abstrakta.
  22. Enneking WF, Soanier SS, Goodman MAS. A system for the staging of musculoskeletal sarcoma. Clin Orthoped Relat Res 1980; 153: 106-120. Go to original source...
  23. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann Intern Med 1069; 71: 747-752. Go to original source...
  24. Gosheger G, Gebert C, Ahrens H, et al. Endoprosthetic reconstruction in 250 patients with sarcoma. Clin Orthop. 2006; 450: 164-174. Go to original source... Go to PubMed...
  25. Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol 2005; 6: 85-92. Go to original source... Go to PubMed...
  26. Kotz RI, Windhager R, Dominkus M, et al. A self-extending pediatric leg implant. Nature. 2000; 406: 143-144. Go to original source... Go to PubMed...
  27. Tomita K, Kawahara H, Murakami H, et al. Total en bloc spondylectomy for spinal tumors: improvement of the technique and its associated basic backround. J Orthop Sci 2006; 11: 3-12. Go to original source... Go to PubMed...
  28. Hoffmann C, Gosheger G, Gebert C, et al. Functional results and quality of life after treatment of pelvic sarcomas involving the acetabulum. J Bone Joint Surg Am. 2006; 88: 575-582. Go to original source... Go to PubMed...
  29. Schwarz R, Bruland O, Cassoni A, et al. The role of radiotherapy in osteosarcoma. Cancer Treat Res 2009; 152: 147-165. Go to original source... Go to PubMed...
  30. Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2003; 21: 334-341. Go to original source... Go to PubMed...
  31. Frenzius C, Bielack S, Flege F, et al. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin. 2001; 40: 215-220. Go to original source... Go to PubMed...
  32. Franzius C, Schuck A, Bielack SS, et al. High-dose Samarium-153 ethylene diamine tetramethylene phophonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20: 1953-1954. Go to original source... Go to PubMed...
  33. Loeb DM, Hobbs RF, Okoli A, et al. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patiens with high-risk osteosarkome. Cancor 2010; 116(23): 5470-5478. Go to original source... Go to PubMed...
  34. Ochs JJ, Freeman AI, Douglass HO, et al. Cis-dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 1978; 62: 239-245. Go to PubMed...
  35. Cortes EP, Holland JF, Wang JJ, et al. Amputation and andriamycin in primary osteosarcoma. N Engl J Med 1974; 291: 998-1000. Go to original source... Go to PubMed...
  36. Jaffe N, Paed D, Farber S. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexatre with citrovorum rescue and radiation therapy. Cancer 1973; 31: 1367-1373. Go to original source...
  37. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology group study. Med Pediatr Oncol 1995; 24: 87-92. Go to original source... Go to PubMed...
  38. Salzer-Kuntschik M, Brand G, Delling G. Bestimmung des morphologischen Regressionsgrade nach Chemotherapie bei malignen Knochentumoren. Pathologie 1983; 4: 135-141.
  39. Sauerbrey A, Bielack S, Kempf-Bielack B, et al. High-dose chemotherapy (HDC) and autologous hematopoietic cell transplantation (ASCI) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transpl 2001; 27: 933-937. Go to original source... Go to PubMed...
  40. Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma: a pilot study. Acta Oncol 1995; 34: 877-880. Go to original source... Go to PubMed...
  41. Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: The EURAMOS experience. Cancer Treat Res 2009; 152: 339-354. Go to original source... Go to PubMed...
  42. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival: a report from the Children´s Oncology Group. J Clin Oncol 2008; 26: 633-638. Go to original source... Go to PubMed...
  43. Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results (letter). J Clin Oncol 2008; 26: 3103-3104. Go to original source... Go to PubMed...
  44. Bielack S, Marina N, Ferrari S, et al. Osteosarcoma: the same old drugs or more? (letter). J Clin Oncol 2008; 26: 3102-3103. Go to original source... Go to PubMed...
  45. Alvarez O, Freeman A, Bedros A, et al. Randomized double-blind crossover ondansetron - dexamethasone versus ondansetron - placebo study for the treatment of chemotherapy - induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995; 17: 145-150. Go to original source... Go to PubMed...
  46. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128. Go to original source... Go to PubMed...
  47. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-2018. Go to original source... Go to PubMed...
  48. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715. Go to original source... Go to PubMed...
  49. Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 20: 559-568. Go to original source... Go to PubMed...
  50. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive Cooperative Osteosarcoma Study Group patients. J Clin Oncol. 2009; 27: 557-565. Go to original source... Go to PubMed...
  51. Carrle D, Bielack SS. Osteosarcoma lung metastases detection and principles of multimodal therapy. Cancer Treat Res. 2009; 152: 165-184. Go to original source... Go to PubMed...
  52. Langer T, Stöhr W, Paulides M, et al. Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS). Klin Pediatr 2005; 217: 176-181. Go to original source... Go to PubMed...
  53. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factor for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-1743. Go to original source... Go to PubMed...
  54. Rossi R, Gödde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk-factors for ifosfamide-induced nephrotoxicity. Analysis of 120 patients. J Clin Oncol 1994; 12: 159-165. Go to original source... Go to PubMed...
  55. Aung L, Gurlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma : Memorial Sloan-Kettering Cancer Center Experience. Cancer. 2002; 95: 1728-1734. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.